Skip to main content
SpringerLink
Log in

The Metabolic Investigation of Erectile Dysfunction: Cardiometabolic Risk Stratification

  • Chapter
  • First Online:
Erectile Dysfunction in Hypertension and Cardiovascular Disease

  • 1043 Accesses

Abstract

This chapter discusses the latest evidence for the metabolic investigation of erectile dysfunction as it relates to cardiometabolic risk and visceral adiposity, the key component of metabolic syndrome. The author illustrates this concept as it relates to the etiology of ED and cardiovascular risk stratification utilizing the latest guidelines of cardiovascular risk released this past year. The author concludes with the levels of evidence for the use of novel biomarkers in the evaluation of the patient with ED as applied to cardiometabolic risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 16.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Hatzimouratidis K, Amar E, Eardley I et al (2010) Guidelines on male sexual dysfunction and premature ejaculation. Eur Urol 57:804–814

    Article  PubMed  Google Scholar 

  2. Prins J, Blanker MH, Bohnen AM et al (2002) Prevalence of erectile dysfunction: a systematic review of population –based studies. Int J Impot Res 14:422–432

    Article  CAS  PubMed  Google Scholar 

  3. Inman BA, St Sauver JL, Jacobson DJ et al (2009) A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 84:108–113.K

    Article  PubMed Central  PubMed  Google Scholar 

  4. Marma AK, Berry JD, Ning H et al (2010) Distribution of 10-year and lifetime predicted risks for cardiovascular disease in US adults findings from the National Health and Nutrition Examination Survey 2003 to 2006. Circ Cardiovasc Qual Outcome 3:8–14

    Google Scholar 

  5. Dhaliwal SS, Welborn TA (2009) Central obesity and multivariable cardiovascular risk as assessed by the Framingham prediction scores. Am J Cardiol 103:1403–1407

    Article  PubMed  Google Scholar 

  6. Stone NJ, Robinson J, Lichtenstein AH et al (2014) 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce astherosclerotic cardiovascular risk in adults. J Am Coll Cardiol 63:2935–59

    Google Scholar 

  7. Nehra A, Jackson G, Miner M et al (2012) The Princeton III consensus recommendations for the management of erectile dysfunction and cardiovascular disease. Mayo Clin Proc 87(8):766–778

    Article  PubMed Central  PubMed  Google Scholar 

  8. Miner M, Nehra A, Jackson G et al (2014) All men with vasculogenic ED require a cardiovascular workup. Am J Med 127(3):174–182

    Article  PubMed  Google Scholar 

  9. Castelli WP, Abbott RD, McNamara PM (1983) Summary estimates of cholesterol used to predict coronary heart disease. Circulation 67(4):730–734

    Article  CAS  PubMed  Google Scholar 

  10. Kassi E, Pervanidou P, Kaltsas G et al (2011) Metabolic syndrome: definitions and controversies. BMC Med 9:48–61

    Article  PubMed Central  PubMed  Google Scholar 

  11. Alberti KG, Eckel RH, Grundy SM et al (2009) International Diabetes Task Force on Epidemiology and Prevention, National Heart, Lung and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society, International Association for the Study of Obesity: harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 120:1640–1645

    Article  CAS  PubMed  Google Scholar 

  12. Aslan Y, Sezgin T, Tuncel A et al (2009) Is type 2 diabetes mellitus a cause of severe erectile dysfunction in patients with metabolic syndrome. Urology 74:561–565

    Article  PubMed  Google Scholar 

  13. Saigal CS, Wessels H, Pace J et al; Urologic Diseases in America Project (2006) Predictors and prevalence of erectile dysfunction in a racially diverse population. Arch Intern Med 166:207–212

    Google Scholar 

  14. Demir T (2006) Prevalence of erectile dysfunction in patients with metabolic syndrome. Int J Urol 13:385–388

    Article  PubMed  Google Scholar 

  15. Bal K, Oder M, Sahin AS et al (2007) Prevalence of metabolic syndrome and its association with erectile dysfunction among urologic patients: metabolic backgrounds of erectile dysfunction. Urology 69:356–360

    Article  PubMed  Google Scholar 

  16. El Sakka AI, Morsy AM (2004) Screening for ischemic heart disease in patients with erectile dysfunction: role of penile Doppler ultrasonography. Urology 64:346–350

    Article  PubMed  Google Scholar 

  17. El-Sakka AI, Morsy AM, Fagih BI et al (2004) Coronary artery risk factors in patients with erectile dysfunction. J Urol 172:251–254

    Article  PubMed  Google Scholar 

  18. Jackson G (2009) Sexual response in cardiovascular disease. J Sex Res 46:233–236

    Article  PubMed  Google Scholar 

  19. Al Hunayan A, Al Mutar M, Kehind EO et al (2007) The prevalence and predictors of erectile dysfunction in men with newly diagnosed with type 2 diabetes mellitus. BJU Int 99:130–134

    Article  PubMed  Google Scholar 

  20. Tomada N, Tomada I, Botelho F et al (2011) Are all metabolic syndrome components responsible for penile hemodynamics impairment in patients with erectile dysfunction? The role of body fat mass assessment. J Sex Med 8:831–839

    Article  PubMed  Google Scholar 

  21. Kupelian V, Shabsig R, Araujo AB et al (2006) Erectile dysfunction as a predictor of the metabolic syndrome in aging men: results from the Massachusetts male aging study. J Urol 176:222–226

    Article  PubMed  Google Scholar 

  22. Corona G, Mannucci E, Ricca V et al (2009) The age related decline of testosterone is associated with different specific symptoms and signs in patients with sexual dysfunction. Int J Androl 32:720–728

    Article  CAS  PubMed  Google Scholar 

  23. Gorbachinsky I, Akpinar H, Assimos DG (2010) Metabolic syndrome and urologic diseases. Rev Urol 12:157–180

    Google Scholar 

  24. Reilly CM, Zamorano P, Stopper VS et al (1997) Androgenic regulation of NO availability in rat penile erection. J Androl 18:110

    CAS  PubMed  Google Scholar 

  25. Shamloul R, Ghanem HM, Salem A et al (2004) Correlation between penile duplex findings and stress electrocardiography in men with erectile dysfunction. Int J Impot Res 16:235–237

    Article  CAS  PubMed  Google Scholar 

  26. Chen CJ, Kuo TB, Tseng YJ et al (2009) Combined cardiac sympathetic excitation and vagal impairment in patients with no organic erectile dysfunction. Clin Neurophysiol 120:348–352

    Article  PubMed  Google Scholar 

  27. Kirby RS, O’Leary MP, Carson C (2005) Efficacy of extended release doxazosin and doxazosin standard in patients with concomitant benign prostatic hyperplasia and sexual dysfunction. BJU Int 95:103–109

    Article  CAS  PubMed  Google Scholar 

  28. De Rose AF, Carmignani G, Corbu C et al (2002) Observational multicentric trial performed with doxazosin: evaluation of sexual effects on patients with diagnosed benign prostatic hyperplasia. Urol Int 68:95–98

    Article  PubMed  Google Scholar 

  29. Liguori G, Trombetta C, De Giorgi G et al (2009) Efficacy of combined oral therapy with tadalafil and alfuzosin: an integrated approach to management of patients with lower urinary tracts symptoms and erectile dysfunction. Preliminary report. J Sex Med 6:544–552

    Article  CAS  PubMed  Google Scholar 

  30. Kaplan SA, Gonzeles RR, Te AE (2007) Combination of alfuzosin and sildenafil is superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. Eur Urol 51:1717–1723

    Article  CAS  PubMed  Google Scholar 

  31. McVary KT (2006) Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 97(Suppl 2):23–28

    Article  PubMed  Google Scholar 

  32. Rosen R, Altwein J, Boyle P et al (2003) Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 44(6):637–649

    Article  PubMed  Google Scholar 

  33. Faris JE, Smith MR (2010) Metabolic sequelae associated with androgen deprivation therapy for prostate cancer. Curr Opin Endocrinol Diabetes Obes 17:240–246

    Article  CAS  PubMed  Google Scholar 

  34. Hammarsten J, Peeker R (2011) Urologic aspects of the metabolic syndrome. Nat Rev Urol 8:483–494

    Article  CAS  PubMed  Google Scholar 

  35. Cohen PG (2008) Obesity in men: the hypogonadal estrogen receptor relationship and its effect on glucose homeostasis. Med Hypotheses 70:358–360

    Article  CAS  PubMed  Google Scholar 

  36. Vermeulen A, Kaufman JM, Deslypere JP et al (1993) Attenuated luteinizing hormone (LH) pulse amplitude but normal pulse frequency, and its relation to plasma androgens in hypogonadism of obese men. J Clin Endocrinol Metab 76:1140–1146

    CAS  PubMed  Google Scholar 

  37. Cohen PG (1998) The role of estradiol in the maintenance of secondary hypogonadism in males in erectile dysfunction. Med Hypotheses 50:331–333

    Article  CAS  PubMed  Google Scholar 

  38. Zumoff B, Miller LK, Strain GW (1993) Reversal of the hypogonadotropic hypogonadism of obese men by administration of the aromatase inhibitor testolactone. Metabolism 52:1126–1128

    Article  Google Scholar 

  39. Rosmond R, Dallman MF, Björntorp P (1998) Stress‑related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 83:1853–1859

    CAS  PubMed  Google Scholar 

  40. Chrousos G (1988) Stressors, stress, and neuroendocrine integration of the adaptive response. The 1997 Hans Selye Memorial Lecture. Ann N Y Acad Sci 851:311–335

    Article  Google Scholar 

  41. Billups KL, Kaiser DR, Kelly AS et al (2003) Relation of C-reactive protein and other cardiovascular risk factors to penile vascular disease in men with erectile dysfunction. Int J Impot Res 15:231–236

    Article  CAS  PubMed  Google Scholar 

  42. Gelfand EV, Cannon CP, Rimonabant (2006) A cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors. JACC 47(10):1919–1926

    Article  CAS  PubMed  Google Scholar 

  43. Vasudevan AR, Ballantyne CM (2005) Cardiometabolic risk assessment: an approach to the prevention of cardiovascular disease and diabetes mellitus. Clin Conerstone 7(2–3):7–16

    Article  Google Scholar 

  44. Centre for evidence-based medicine. http://www.cebm.net/levels_of_evidence.asp

  45. Rathmann W, Haastert B, Herder C et al (2007) Differential association of adiponectin with cardiovascular risk markers in men and women? The KORA survey 2000. Int J Obes 31:770–776

    CAS  Google Scholar 

  46. Yamauchi T, Kamon J, Minokoshi Y et al (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295

    Article  CAS  PubMed  Google Scholar 

  47. Snijder MB, Heine RJ, Seidell JC et al (2006) Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women. The Hoorn study. Diabetes Care 29:2498–2503

    Article  CAS  PubMed  Google Scholar 

  48. Silvestro A, Brevetti G, Schiano V et al (2005) Adhesion molecules and cardiovascular risk in peripheral arterial disease. Soluble vascular cell adhesion molecule-1 improves risk stratification. Thromb Haemost 93:559–563

    CAS  PubMed  Google Scholar 

  49. Nikoobakht M, Nasseh H, Pourkasmaee M (2005) The relationship between lipid profile and erectile dysfunction. Int J Impot Res 17:523–526

    Article  CAS  PubMed  Google Scholar 

  50. Burke JP, Jacobson DJ, McGree ME et al (2007) Diabetes and sexual dysfunction: results from the Olmsted county study of urinary symptoms and health status among men. J Urol 177:1438–1442

    Article  PubMed  Google Scholar 

  51. Ponholzer A, Temml C, Mock K et al (2005) Prevalence and risk factors for erectile dysfunction in 2869 men using a validated questionnaire. Eur Urol 47:80–85

    Article  PubMed  Google Scholar 

  52. Fonseca V, Jawa A (2005) Endothelial and erectile dysfunction, diabetes mellitus, and the metabolic syndrome: common pathways and treatments? Am J Cardiol 96:13M–18M

    Article  PubMed  Google Scholar 

  53. Vinik A, Richardson D (1998) Erectile dysfunction in diabetes. Diabetes Rev 6:16–33

    Google Scholar 

  54. Fedele D, Coscelli C, Santeusanio F et al (1998) For the Gruppo Italiano Studio Deficit Erecttile nei Diabetici. Erectile dysfunction in diabetic subjects in Italy. Diabetes Care 21:1973–1977

    Article  CAS  PubMed  Google Scholar 

  55. Braun M, Wassmer G, Klotz T et al (2000) Epidemiology of erectile dysfunction: results of the ‘Cologne male survey’. Int J Imp Res 12:305–311

    Article  CAS  Google Scholar 

  56. Bacon CG, Hu FB, Giovannucci E et al (2002) Association and type and duration of diabetes with erectile dysfunction in a large cohort of men. Diabetes Care 25:1458–1463

    Article  PubMed  Google Scholar 

  57. Rhoden EL, Ribeiro EP, Riedner CE et al (2005) Glycosolated hemoglobin levels and the severity of erectile function in diabetic men. BJU Int 95:615–617

    Article  CAS  PubMed  Google Scholar 

  58. Gazzaruso C, Pujia A, Solerte SB et al (2006) Erectile dysfunction and angiographic extent of coronary artery disease in type II diabetic patients. Int J Impot Res 18:311–315

    Article  CAS  PubMed  Google Scholar 

  59. Naya M, Tsukamoto T, Morita K et al (2007) Plasma interleukin-6 and tumor necrosis factor-alpha can predict coronary endothelial dysfunction in hypertensive patients. Hypertens Res 30:541–548

    Article  CAS  PubMed  Google Scholar 

  60. Vlachopoulos C, Aznaouridis K, Ioakeimidis N et al (2006) Unfavourable endothelial and inflammatory state in erectile dysfunction patients with or without coronary artery disease. Eur Heart J 27:2640–2648

    Article  CAS  PubMed  Google Scholar 

  61. Giugliano F, Esposito K, Di Palo C et al (2004) Erectile dysfunction associates with endothelial dysfunction and raised proinflammatory cytokine levels in obese men. J Endocrinol Invest 27:665–669

    Article  CAS  PubMed  Google Scholar 

  62. Mulligan T, Frick MF, Zuraw QC et al (2006) Prevalence of hypogonadism in males at least 45 years: the HIM study. Int J Clin Pract 60:762–769

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Buvat J, Maggi M, Guay A et al (2013) Testosterone deficiency in Men: systematic review and standard operating procedures for diagnosis and treatment. J Sex Med 10:245–284

    Article  CAS  PubMed  Google Scholar 

  64. Miner M, Canty D, Shabsigh R (2008) Testosterone replacement therapy in hypogonadal men: assessing benefits, risks, and best practices. Postgrad Med 120(3):130–152

    Article  PubMed  Google Scholar 

  65. Shabsigh R, Kaufman JM, Steidle C et al (2004) Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 172(2):658–663

    Article  CAS  PubMed  Google Scholar 

  66. Tota-Maharaj R, Blaha MJ (2012) Coronary artery calcium for the prediction of mortality in young adults <45 years old and elderly adults >75 years old. Eur Heart J 33:2955–2962

    Article  CAS  PubMed  Google Scholar 

  67. Detrano R, Guerci AD, Carr JJ et al (2008) Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 358:1336–1345

    Article  CAS  PubMed  Google Scholar 

  68. Cooke JP (2000) The endothelium: a new target for therapy. Vasc Med 5:49–53

    Article  CAS  PubMed  Google Scholar 

  69. Lekakis J, Papamichael C, Vemmos C et al (1998) Effects of acute cigarette smoking on endothelium-dependent arterial dilatation in normal subjects. Am J Cardiol 81:1225–1228

    Article  CAS  PubMed  Google Scholar 

  70. Higashi Y, Sasaki S, Nakagawa K et al (2001) Effect of obesity on endothelium-dependent, nitric oxide-mediated vasodilation in normotensive individuals and patients with essential hypertension. Am J Hypertens 14:1038–1045

    Article  CAS  PubMed  Google Scholar 

  71. Kaiser DR, Billups KL, Bank AL et al (2004) Impaired brachial artery endothelium-dependent and –independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 43:179–184

    Article  PubMed  Google Scholar 

  72. Shabsigh R (2005) Correlation between erectile dysfunction and metabolic syndrome. In: Sadovsky R (ed) Heart of the matter: erectile dysfunction as an early sign of vasculopathy. CogniMed Inc, Livingston, pp 14–21

    Google Scholar 

  73. Segura J, Ruilope LM (2007) Obesity, essential hypertension and rennin-angiotensin system. Public Health Nutr 10:1151–1155

    Article  PubMed  Google Scholar 

  74. Yamagishi S, Ueda S, Nakamura K et al (2008) Role of asymmetric dimethylarginine (ADMA) in diabetic vascular complications. Curr Pharm Des 25:2613–2618

    Article  Google Scholar 

  75. Palmer RM, Ferrige AG, Moncada S (1987) Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524–526

    Article  CAS  PubMed  Google Scholar 

  76. Juonala M, Viikari J, Alfthan G et al (2007) Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation 116:1367–1373

    Article  PubMed  Google Scholar 

  77. Ardigo D, Stuehlinger M, Franzini L et al (2007) ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest 37:263–269

    Article  CAS  PubMed  Google Scholar 

  78. Valkonen V, Paiva H, Salonen J et al (2001) Risk of acute coronary events and serum concentration of asymmetric dimethylarginine. Lancet 358:2127–2128

    Article  CAS  PubMed  Google Scholar 

  79. Mittermayer F, Krzyzanowska K, Exner M et al (2006) Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 26:2536–2540

    Article  CAS  PubMed  Google Scholar 

  80. Schnabel R, Blankenberg S, Lubos E et al (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene study. Circ Res 97:e53–e59

    Article  CAS  PubMed  Google Scholar 

  81. Maas R, Wenske S, Zabel M et al (2005) Elevation of asymmetric dimethylarginine (ADMA) and coronary artery disease in men with erectile dysfunction. Eur Urol 48:1004–1011

    Article  PubMed  Google Scholar 

  82. Cooke JP (2000) Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 20:2032–2037

    Article  CAS  PubMed  Google Scholar 

  83. Kielstein JT, Impraim B, Simmel S et al (2004) Cardiovascular effects of systemic nitric oxide synthase inhibition with ADMA in humans. Circulation 109:172–177

    Article  CAS  PubMed  Google Scholar 

  84. Judd S, Tangpricha V (1989) Vitamin D deficiency and risk for cardiovascular disease. Lancet 1:613

    Google Scholar 

  85. Hollick MF, Binkley NC, Heike BA et al (2011) Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 96:1911–1930

    Article  Google Scholar 

  86. Wallis D, Penckofer S, Sizemore G (2008) The “sunshine deficit” and cardiovascular disease. Circulation 118:1476–1485

    Article  PubMed  Google Scholar 

  87. Kuhn T, Kaaks R (2008) Plasma 25-hydroxyvitamin D and its genetic determinants in relation to incident myocardial infarction and stroke in the European Prospective Investigation into Cancer and nutrition (EPIC)-Germany study. Arch Int Med 168:1174–1180

    Article  Google Scholar 

  88. Mullie P, Autier P (2010) Relation of vitamin D deficiency to cardiovascular disease. Am J Cardiol 106:963–968

    Article  Google Scholar 

  89. de Boer I, Kestenbaum B, Shoben A et al (2009) 25-hyddroxyvitamin D levels inversely associate with risk for developing coronary artery calcification. J Am Soc Nephrol 20:1805–1812

    Article  PubMed Central  PubMed  Google Scholar 

  90. Danik J, Manson J (2012) Vitamin D and cardiovascular disease. Curr Treat Options Cardiovasc Med 14:414–424

    Article  PubMed Central  PubMed  Google Scholar 

  91. Goff DC Jr, Lloyd-Jones DM, Bennett G (2014) 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 63:2935–59

    Google Scholar 

  92. Thompson IM, Tamgen CM, Goodman PJ et al (2005) Erectile dysfunction and subsequent cardiovascular disease. JAMA 294:2296–3002

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Family Medicine and Urology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA

    Martin Miner MD

  2. Men’s Health Center, The Miriam Hospital, 164 Summit Ave, Providence, RI, USA

    Martin Miner MD

Authors
  1. Martin Miner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Martin Miner MD .

Editor information

Editors and Affiliations

  1. Tallinn University of Technology, North Estonia Medical Centre, Tallinn, Estonia

    Margus Viigimaa

  2. Athens Medical School, Athens, Greece

    Charalambos Vlachopoulos

  3. Internal Medicine, Aristotle University, Thessaloniki, Greece

    Michael Doumas

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Miner, M. (2015). The Metabolic Investigation of Erectile Dysfunction: Cardiometabolic Risk Stratification. In: Viigimaa, M., Vlachopoulos, C., Doumas, M. (eds) Erectile Dysfunction in Hypertension and Cardiovascular Disease. Springer, Cham. https://doi.org/10.1007/978-3-319-08272-1_15

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08272-1_15

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-08271-4

  • Online ISBN: 978-3-319-08272-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation